Chiasma snags $70 mln Series E

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.


VC-backed Ascendis Pharma goes public

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

VC-backed Histogenics goes public

Waltham, Mass.-based Histogenics Corp., a regenerative medicine developer, has debuted its IPO after pricing its 5.9 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “HSGX.” Cowen and Co., Needham & Co. and Canaccord Genuity are the lead underwriters. Histogenics’ backers include Sofinnova Ventures, Split Rock Partners and Altima Partners.


Deerfield leads $42.5 mln round for Audentes

San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes’ board of directors.


Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma

Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma’s largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company’s board of directors.


Aclaris attracts $21 mln Series B

Aclaris Therapeutics said Thursday that it has received $21 million in Series B financing. The investors were return backers Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Based in Malvern, Penn., Aclaris Therapeutics is a specialty pharmaceutical firm focused on developing a treatment that removes various skin lesions.


Civitas Therapeutics scores $55 mln Series C

Civitas Therapeutics has closed $55 million in Series C funding. The investors included Adage Capital Management, OrbiMed Advisors, Partner Fund Management, Rock Springs Capital, Sofinnova Ventures, Canaan Partners, RA Capital and Wellington Management Company. Headquartered in Chelsea, Mass., Civitas Therapeutics is a biopharmaceutical company that focuses on developing treatments for Parkinson’s disease.


Big data analytics firm Guavus fetches $20 mln

Guavus has received $20 million in funding. The investors included Artiman Ventures, Sofinnova Ventures, Intel Capital, SingTel Innov8, Investor Growth Capital, QuestMark Partners and Goldman Sachs. Based in San Mateo, Calif., Guavus is a provider of big data analytics solutions for operational intelligence.

vc top 10 larry shutterstock_121959277

Top 10 posts: venture capital

Trending in VC this week on peHUB: Surf Air takes to sky with $73 million, Sammy Hagar rocks a deal for DripDrop, and women still find it difficult to break into Silicon Valley’s VC club.

VC-backed Sorbent Therapeutics expands board of directors

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.


Teva agrees to buy VC-backed Labrys for up to $825 mln

sraeli pharmaceutical company Teva Pharmaceutical Industries has agreed to acquire Labrys Biologics for $200 million in upfront payment in cash as well as up to $625 million in payments based on achievement of certain pre-launch milestones. Based in San Mateo, Calif., Labrys is a biotech firm focused on treating migraine. It was backed by venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget